About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Maryland | 652 Studies

Clinical Trials Lung CancerMaryland

Lung Cancer Clinical Trials in Maryland

Find 652 clinical trials for lung cancer near Maryland. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Maryland

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 101-120 of 652 trials

CompletedPhase 1/1b Study of MGCD516 in Patients With Advanced CancerMGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR…NCT02219711·Birmingham, Alabama and 42 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingGEMINI-NSCLC: NSCLC Biomarker StudyGEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood…NCT05236114·Birmingham, Alabama and 57 others

TerminatedA Study of Ladiratuzumab Vedotin in Advanced Solid TumorsThis trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors.NCT04032704·Chandler, Arizona and 65 others

RecruitingA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC.NCT07098338·Santa Monica, California and 82 others

Active not recruitingGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsThe goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without…NCT04083599·Anchorage, Alaska and 75 others

CompletedLMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian CancerPhase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer.NCT00005858·Baltimore, Maryland and 1 other

No longer availableExpanded Treatment Protocol With LDK378 in ALK(+) NSCLCNovartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in…NCT01947608·Chandler, Arizona and 49 others

Active not recruitingAvelumab Program Rollover StudyThe main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same…NCT03815643·Scottsdale, Arizona and 103 others

CompletedA Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer PatientsTaxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens.NCT00085826·Birmingham, Alabama and 113 others

RecruitingPredicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a…NCT07327489·Fort Smith, Arkansas and 7 others

RecruitingPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsThe purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as…NCT06357533·Anchorage, Alaska and 289 others

CompletedT Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerBackground: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from…NCT01967823·Bethesda, Maryland

CompletedKEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or…NCT04165083·Gilbert, Arizona and 38 others

CompletedVaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced TumorsRATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells.NCT00003125·Washington D.C., District of Columbia and 1 other

RecruitingA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPhase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2…NCT03093116·Duarte, California and 164 others

RecruitingA Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsThis study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.NCT07020221·Los Angeles, California and 21 others

CompletedFR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00020202·Bethesda, Maryland

TerminatedRadiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerThis randomized phase III trial is studying whole-brain radiation therapy and stereotactic radiosurgery with or without temozolomide or erlotinib to see how well they work…NCT00096265·Scottsdale, Arizona and 82 others

UnknownTomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLCNCT04622007·Daphne, Alabama and 143 others

TerminatedNGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) TrialThis is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential…NCT04698681·Daphne, Alabama and 62 others

PreviousPage 6 of 33Next

Other Conditions in Maryland

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma